Phase 1b Trial Reported Approximately 65% Pathological Response in cSCC, Including Complete Responses at Maximum Dose, ...
This February, as the global healthcare community convened in Dubai for World Health Expo, MillerKnoll helped shape the conversation around how clinical environments can better support the people who ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results